EMA, ECDC reiterate need for vaccination

Portfolio
Full vaccination is key to protecting against serious COVID-19, including disease caused by the Delta variant, the European Medicines Agency (EMA) and the European Centre for Disease Prevention and Control (ECDC) said in a joint statement on Wednesday. Full vaccination with any of the EU/EEA-approved vaccines offers a high level of protection against severe disease and death caused by SARS-CoV-2, including variants, such as Delta.
covid_koronavirus_vakcina_oltas

The two EU agencies strongly encourage those who are eligible for vaccination but have not yet been vaccinated to start and complete the recommended COVID-19 vaccination schedule in a timely manner.

Vaccination is also important for protecting those at highest risk of severe disease and hospitalisation, reducing the spread of the virus, and preventing the emergence of new variants of concern, the statement highlighted.

Infections in vaccinated people do not mean that vaccines do not work.

Although the effectiveness of all COVID-19 vaccines authorised in the EU is very high, no vaccine is 100% effective. This means that a limited number of SARS-CoV-2 infections among persons that have completed the recommended vaccination schedule (i.e. ‘breakthrough infections’) are expected. However, when infections do occur, vaccines can prevent severe disease to a large extent, and greatly reduce the number of people in hospital due to COVID-19.

Vaccinated people are far better protected against severe COVID-19 than unvaccinated people, and we should all endeavour to be fully vaccinated at the earliest opportunity,

Fergus Sweeney, EMA’s Head of Clinical Studies and Manufacturing said.

The EMA has so far recommended the use of Pfizer/BioNTech’s Comirnaty, AstraZeneca’s Vaxzevira, Moderna’s Spikevax, and Johnson & Johnson’s vaccine. It is also examining the Russian-made Sputnik V, Sanofi’s Vidprevtyn, CureVac’s CVnCoV, as well as the vaccines of Sinovac and Novavax.

Cover photo: Getty Images

More in Business

December 08, 2023 15:56

MVM buys one of Hungary's largest solar power plants

Transaction closed

December 06, 2023 16:21

MVM's new strategy to double renewable capacity in Hungary by 2025

They will either buy or build solar power plants

BJASZ20200225022
December 06, 2023 09:45

Nitrogénművek downgraded by Fitch

The company has multiple problems

pfizer vakcina gyógyszergyártó
December 06, 2023 09:31

Pfizer and BioNTech sue the Hungarian government over 3 million doses of Covid vaccines

The state has not paid for €60 million worth of shipments

December 05, 2023 15:04

U.S. supplier ventures into EV territory in Hungary

With EUR 60 million investment

Mol Dunai Finomító Dufi munkás
December 05, 2023 12:10

Hungary Mol buys stake in Waberer's

Parties ink new strategic partnership agreement too